Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Werewolf Therapeutics Inc

HOWL
Current price
2.7 USD -0.02 USD (-0.74%)
Last closed 2.75 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 92 290 112 USD
Yield for 12 month +65.64 %
Week
Month
Year
HOWL
21.11.2021 - 28.11.2021

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. Address: 1030 Massachusetts Avenue, Cambridge, MA, United States, 02138

Analytics

WallStreet Target Price

12.8 USD

P/E ratio

Dividend Yield

Current Year

+16 401 000 USD

Last Year

Current Quarter

+5 897 000 USD

Last Quarter

+8 081 000 USD

Current Year

+16 401 000 USD

Last Year

Current Quarter

+5 897 000 USD

Last Quarter

+8 081 000 USD

Key Figures HOWL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -38 999 000 USD
Operating Margin TTM -156.88 %
PE Ratio
Return On Assets TTM -14.59 %
PEG Ratio
Return On Equity TTM -30.65 %
Wall Street Target Price 12.8 USD
Revenue TTM 25 725 000 USD
Book Value 3.15 USD
Revenue Per Share TTM 0.75 USD
Dividend Share
Quarterly Revenue Growth YOY 18.7 %
Dividend Yield
Gross Profit TTM -37 360 000 USD
Earnings Share -1.1 USD
Diluted Eps TTM -1.1 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -144.98 %

Dividend Analytics HOWL

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History HOWL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation HOWL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.5606
Price Sales TTM 3.5876
Enterprise Value EBITDA -0.3698
Price Book MRQ 0.8208

Financials HOWL

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators HOWL

For 52 weeks

1.39 USD 4.57 USD
50 Day MA 2.3 USD
Shares Short Prior Month 318 371
200 Day MA 2.66 USD
Short Ratio 0.23
Shares Short 518 488
Short Percent 2.81 %